Colorectal Cancer Colorectal cancer is the second leading cause of cancer mortality in men and women in Europe1. The number of cases is expected to increase over the next two decades as a result of the aging population. This high mortality rate is due to the silent development of the disease as symptoms appear only
Mars Bleu, a campaign to raise awareness about colorectal cancer screening You may have heard about Pink October, a month dedicated to breast cancer awareness and screening. If you didn’t know it yet, there is also the national colorectal cancer awareness month; it’s March and it’s called Mars Bleu (Blue March). Colorectal cancer is
Geneva pharmacies engage in the fight against colorectal cancer The campaign “Mars Bleu” (Blue March) is an opportunity to develop a new network and to make screening even more accessible. In March, 20 Geneva’s drug stores partner with Novigenix for the fight against colorectal cancer by promoting different non-invasive screening solutions including the molecular
Agreement significantly increases access to Colox® in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017 – Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold
Data validate blood-based test’s ability to detect colorectal cancer early and reliably LAUSANNE, Switzerland, May 9, 2015 – Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with